Nkarta (NKTX) Stock: Buy, Sell, or Hold?
NKTX - Nkarta, Inc. Common Stock
$2.91
0.10 (3.56%)
▲
5d:
+4.3%
30d:
+21.76%
90d:
+5.43%
WAIT
LOW Confidence
Analysis Updated: Sep 11, 2026 12:00 AM ET
Earnings: Aug 11, 2026
0d
Get Alerted When NKTX Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 MIXED SIGNALS: NKTX shows conflicting indicators. Wait for confirmation before entering.
📊 MIXED SIGNALS: NKTX shows conflicting indicators. Wait for confirmation before entering.
In-depth Analysis How we analyze
Valuation Analysis: NKTX is currently trading at $2.91, which is considered extended relative to its 30-day fair value range of $2.30 to $2.83.
Technical Outlook: Technically, NKTX is in a downtrend. Immediate support is located at $2.62, while resistance sits at $3.30. The stock is showing strong short-term momentum, up 3.6% recently.
Market Sentiment: NKTX scores 15/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $10.83 (+272.3%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, NKTX is in a downtrend. Immediate support is located at $2.62, while resistance sits at $3.30. The stock is showing strong short-term momentum, up 3.6% recently.
Market Sentiment: NKTX scores 15/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $10.83 (+272.3%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$2.30 -
$2.83
Company Quality Score
37/100
(SELL)
Volume Confirmation
HIGH
Confidence Score
31.6%
All Signals
- BEARISH: Price extended above range
- BEARISH: Weak technical setup (15/100)
- BULLISH: High volume confirmation
- BULLISH: Strong upward momentum (+3.6%)
- BULLISH: Trading 272.3% below Wall St target ($10.83)
- WARNING: Composite score 37/100 in the bottom quintile — this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$2.30 -
$2.83
Current vs Trading Range
EXTENDED
Support & Resistance Levels
Support Level
$2.62
Resistance Level
$3.30
Current Trend
Downtrend
Technical data as of
Sep 11, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-1.66
Wall Street Target
$10.83
(+272.3%)
Share & Embed Analysis
Last updated: September 12, 2026 9:25 PM ET
Data refreshes hourly during market hours. Next update: 10:25 PM
Data refreshes hourly during market hours. Next update: 10:25 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is NKTX showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
ALNY
Alnylam Pharmaceuticals … |
STRONG BUY
30 analysts |
$370 | 43 HOLD |
|
ONC
BeiGene, Ltd. |
STRONG BUY
24 analysts |
$432 | 48 HOLD |
|
VRTX
Vertex Pharmaceuticals I… |
BUY
34 analysts |
$570 | 38 SELL |
|
ASND
Ascendis Pharma AS |
STRONG BUY
16 analysts |
$315 | 47 HOLD |
|
APLS
Apellis Pharmaceuticals … |
BUY
22 analysts |
$41 | 50 HOLD |
